Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMERIS: Umbilical Cord MSCs for Acute Ischemic Stroke
NCT06518902Phase 1Not yet recruiting
- Sponsor
- National Engineering Center of Cell Products
- Start
- Aug 2024
- Primary completion
- Jul 2025
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in ischemic stroke, sponsored by National Engineering Center of Cell Products. Primary endpoint: Dose-limiting toxicity at 6 months. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06518902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06518902.